Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
- Cabrero, M.
- López-Corral, L.
- Jarque, I.
- de la Cruz-Vicente, F.
- Pérez- López, E.
- Valcárcel, D.
- Sanz, J.
- Espigado, I.
- Ortí, G.
- Martín- Calvo, C.
- de la Serna, J.
- Caballero, D.
ISSN: 1476-5365, 0268-3369
Datum der Publikation: 2024
Ausgabe: 59
Nummer: 3
Seiten: 359-365
Art: Artikel